TRIM38 triggers the ubiquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer

[1] Antoni S(2017)Bladder cancer incidence and mortality: a global overview and recent trends Eur Urol 71 96-108

[2] Ferlay J(2019)Secular trends in incidence and mortality of bladder cancer in China, 1990–2017: a joinpoint and age-period-cohort analysis Cancer Epidemiol 61 95-103

[3] Soerjomataram I(2020)Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology J Natl Compr Cancer Netw 18 329-354

[4] Znaor A(2021)Cancer statistics, 2021 CA Cancer J Clin 71 7-33

[5] Jemal A(2020)Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer J Urol 203 902-909

[6] Bray F(2021)Examining the accuracy of self-reported smoking-related exposure among recently diagnosed nonmuscle invasive bladder cancer patients J Urol 205 1321-1325

[7] Liu X(2020)KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC Future Oncol 16 507-516

[8] Jiang J(2019)European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update Eur Urol 76 639-657

[9] Yu C(2020)The natural history of untreated muscle-invasive bladder cancer BJU Int 125 270-275

[10] Wang Y(2020)Traditional classification and novel subtyping systems for bladder cancer Front Oncol 10 102-423

[1] Antoni S(2017)Bladder cancer incidence and mortality: a global overview and recent trends Eur Urol 71 96-108

[2] Ferlay J(2019)Secular trends in incidence and mortality of bladder cancer in China, 1990–2017: a joinpoint and age-period-cohort analysis Cancer Epidemiol 61 95-103

[3] Soerjomataram I(2020)Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology J Natl Compr Cancer Netw 18 329-354

[4] Znaor A(2021)Cancer statistics, 2021 CA Cancer J Clin 71 7-33

[5] Jemal A(2020)Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer J Urol 203 902-909

[6] Bray F(2021)Examining the accuracy of self-reported smoking-related exposure among recently diagnosed nonmuscle invasive bladder cancer patients J Urol 205 1321-1325

[7] Liu X(2020)KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC Future Oncol 16 507-516

[8] Jiang J(2019)European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update Eur Urol 76 639-657

[9] Yu C(2020)The natural history of untreated muscle-invasive bladder cancer BJU Int 125 270-275

[10] Wang Y(2020)Traditional classification and novel subtyping systems for bladder cancer Front Oncol 10 102-423